Stay updated on Safety and Efficacy of MEDI0457 and Durvalumab in HPV+ HNC Clinical Trial
Sign up to get notified when there's something new on the Safety and Efficacy of MEDI0457 and Durvalumab in HPV+ HNC Clinical Trial page.

Latest updates to the Safety and Efficacy of MEDI0457 and Durvalumab in HPV+ HNC Clinical Trial page
- Check4 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check11 days agoNo Change Detected
- Check19 days agoChange DetectedDifference0.0%

- Check33 days agoChange DetectedRevision updated to v3.5.0; revision v3.4.3 was removed.SummaryDifference0.0%

- Check41 days agoChange DetectedRevision: v3.4.3 added and v3.4.2 removed; this is a minor versioning update with no changes to study data or page behavior.SummaryDifference0.0%

- Check55 days agoChange DetectedAdded 'Oropharynx cancer' as a related condition and a new 'Genetic and Rare Diseases Information Center' resource under Resources.SummaryDifference0.1%

- Check69 days agoChange DetectedAdded Revision: v3.4.2 and removed Revision: v3.4.1, and removed the government funding status notice about potential delays.SummaryDifference0.3%

Stay in the know with updates to Safety and Efficacy of MEDI0457 and Durvalumab in HPV+ HNC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety and Efficacy of MEDI0457 and Durvalumab in HPV+ HNC Clinical Trial page.